Immune-Markers in GallBladder Lesions and their Clinico-Diagnostic and Prognostic Significance - An Overview

Simple item page
dc.contributor.authorAgarwal, A.en_US
dc.contributor.authorAlRawaili, A. M.en_US
dc.contributor.authorAlZalbani, M. K.en_US
dc.contributor.authorAlAnazi, G. K.en_US
dc.contributor.authorAlAnazi, S. K.en_US
dc.contributor.authorAlEnezi, S. A. D.en_US
dc.date.accessioned2024-09-24T08:28:02Z
dc.date.available2024-09-24T08:28:02Z
dc.date.issued2023-03
dc.description.abstractGallbladder benign diseases are common and usually cured without further consequences. Some benign illnesses increase the chance of cancer development significantly, whereas others resemble malignant disorders. The biomarkers discussed thus far are among the most extensively researched concerning the different diseases of GBC. Patients with gallbladder cancer are usually diagnosed in later stages when conventional treatments are ineffective. The lack of responsiveness of advanced instances of GBC to existing therapies necessitates the identification of novel prognostic and therapeutic approaches. Novel prognostic biomarkers may provide a crucial breakthrough in this area. Despite the available data and years of research, a prognostic marker that is 100% specific and sensitive to GBC is not yet available. A diverse number of molecular markers have been studied for their potential to be prognostic markers in GBC. p53 and HER2 have been studied very extensively and have shown promise. The deregulation and accumulation of the molecular markers we have discussed so far impact carcinogenesis of the gall bladder. Further analytical studies on the concentration levels of these markers in normal vs precancerous vs cancerous tissues should be carried out. Highly specific prognostic markers can help individualize treatment options to bring down the mortality rate in GBC.en_US
dc.identifier.affiliationsDepartment of Pathology, Faculty of Medicine, Northern Border University, Saudi Arabiaen_US
dc.identifier.affiliationsFaculty of Medicine, Northern Border University, Saudi Arabiaen_US
dc.identifier.affiliationsFaculty of Medicine, Northern Border University, Saudi Arabiaen_US
dc.identifier.affiliationsFaculty of Medicine, Northern Border University, Saudi Arabiaen_US
dc.identifier.affiliationsFaculty of Medicine, Northern Border University, Saudi Arabiaen_US
dc.identifier.affiliationsFaculty of Medicine, Northern Border University, Saudi Arabiaen_US
dc.identifier.citationAgarwal A., AlRawaili A. M., AlZalbani M. K., AlAnazi G. K., AlAnazi S. K., AlEnezi S. A. D. . Immune-Markers in GallBladder Lesions and their Clinico-Diagnostic and Prognostic Significance - An Overview . International Journal of Pharmaceutical Research and Allied Sciences . 2023 Jan; 12(1): 47-58en_US
dc.identifier.issn2277-3657
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/231404
dc.languageenen_US
dc.publisherMeral Publisheren_US
dc.relation.issuenumber1en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.51847/NBEs0VKQMpen_US
dc.subjectGallbladderen_US
dc.subjectGallbladder canceren_US
dc.subjectImmune-markersen_US
dc.subjectClinico-diagnostic significanceen_US
dc.subjectPrognostic significanceen_US
dc.titleImmune-Markers in GallBladder Lesions and their Clinico-Diagnostic and Prognostic Significance - An Overviewen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijpras2023v12n1p47.pdf
Size:
419.81 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Pharmaceutical Research and Allied Sciences